Insights
Insights/ Market Access/ Views & Analysis/ Views and analysis
Spotlight on women in pharma: Şeyda Atadan Memiş, Takeda
Eloise McLennan
industry, Life Sciences, market access, medicines, pharma, Takeda, women
0 Comment
Insights/ Market Access/ Views & Analysis/ Views and analysis
Is the launch environment really more competitive now?
mike.hammerton@pharmaphorum.com
competitive intensity, IQVIA, launch environment, market data, pharma, primary care
0 Comment
Insights/ Market Access/ Pharma Market Access/ Quintiles - Oncol articles/ White Papers/ Whitepapers
Standing on the cusp of something great: How real-world data is poised to transform cancer care
Adam Jeffery
cancer, Drug regulation, IQVIA, Oncology, patient data, pharma, Real World Evidence
0 Comment
Insights/ Insights/ Market Access/ R&D/ Slider in whitepapers/ White Papers/ Whitepapers
Pricing and Market Access Outlook 2018
Linda Banks
HTA, market access, pharma pricing, pricing strategy
0 Comment
Insights/ Insights/ Market Access/ Pharma Market Access/ R&D/ Slider in whitepapers/ White Papers/ Whitepapers
Pricing and market access – facts versus fiction
sally.macaulay@pharmaphorum.com
0 Comment
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.
Digital/ Digital and Social Media/ Insights/ Insights/ Market Access/ Sales and Marketing/ White Papers/ Whitepapers
Big data in Life Sciences: the time for strategy is now
Craig Sharp
big data, Life Sciences, Sales and Marketing, Zephyr Health
0 Comment
Insights/ Market Access/ Pharma Market Access/ White Papers/ Whitepapers
Pricing & Market Access Outlook 2015/2016 Edition
Insights/ Market Access/ Pharma Market Access/ White Papers/ Whitepapers